Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Outcomes of treatment for the patient subgroup with MET overexpression

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Chong Kin Liam (15331321) (author)
مؤلفون آخرون:	Azura Rozila Ahmad (15331324) (author), Te-Chun Hsia (15331327) (author), Jianying Zhou (15331330) (author), Dong-Wan Kim (15036467) (author), Ross Andrew Soo (15331333) (author), Ying Cheng (15331336) (author), Shun Lu (15331339) (author), Sang Won Shin (15331342) (author), James Chih-Hsin Yang (15048002) (author), Yiping Zhang (15331345) (author), Jun Zhao (11571833) (author), Karin Berghoff (15331348) (author), Rolf Bruns (15331351) (author), Andreas Johne (15331354) (author), Yi-Long Wu (11678896) (author)
منشور في:	2025
الموضوعات:	Cancer Therapeutic Research and Development Clinical Research and Trials Chemotherapy Clinical Trial Results Clinical-Stage Research Drug Resistance Lung Cancer Precision Medicine Small Molecule Agents
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

_version_	1849927633708515328
author	Chong Kin Liam (15331321)
author2	Azura Rozila Ahmad (15331324) Te-Chun Hsia (15331327) Jianying Zhou (15331330) Dong-Wan Kim (15036467) Ross Andrew Soo (15331333) Ying Cheng (15331336) Shun Lu (15331339) Sang Won Shin (15331342) James Chih-Hsin Yang (15048002) Yiping Zhang (15331345) Jun Zhao (11571833) Karin Berghoff (15331348) Rolf Bruns (15331351) Andreas Johne (15331354) Yi-Long Wu (11678896)
author2_role	author author author author author author author author author author author author author author author
author_facet	Chong Kin Liam (15331321) Azura Rozila Ahmad (15331324) Te-Chun Hsia (15331327) Jianying Zhou (15331330) Dong-Wan Kim (15036467) Ross Andrew Soo (15331333) Ying Cheng (15331336) Shun Lu (15331339) Sang Won Shin (15331342) James Chih-Hsin Yang (15048002) Yiping Zhang (15331345) Jun Zhao (11571833) Karin Berghoff (15331348) Rolf Bruns (15331351) Andreas Johne (15331354) Yi-Long Wu (11678896)
author_role	author
dc.creator.none.fl_str_mv	Chong Kin Liam (15331321) Azura Rozila Ahmad (15331324) Te-Chun Hsia (15331327) Jianying Zhou (15331330) Dong-Wan Kim (15036467) Ross Andrew Soo (15331333) Ying Cheng (15331336) Shun Lu (15331339) Sang Won Shin (15331342) James Chih-Hsin Yang (15048002) Yiping Zhang (15331345) Jun Zhao (11571833) Karin Berghoff (15331348) Rolf Bruns (15331351) Andreas Johne (15331354) Yi-Long Wu (11678896)
dc.date.none.fl_str_mv	2025-11-25T13:01:32Z
dc.identifier.none.fl_str_mv	10.1158/1078-0432.30706779
dc.relation.none.fl_str_mv	https://figshare.com/articles/figure/Supplementary_Figure_S3_from_Randomized_Trial_of_Tepotinib_Plus_Gefitinib_versus_Chemotherapy_in_i_EGFR_i_-Mutant_NSCLC_with_EGFR_Inhibitor_Resistance_Due_to_i_MET_i_Amplification_INSIGHT_Final_Analysis/30706779
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Therapeutic Research and Development Clinical Research and Trials Chemotherapy Clinical Trial Results Clinical-Stage Research Drug Resistance Lung Cancer Precision Medicine Small Molecule Agents
dc.title.none.fl_str_mv	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
dc.type.none.fl_str_mv	Image Figure info:eu-repo/semantics/publishedVersion image
description	<p>Outcomes of treatment for the patient subgroup with MET overexpression</p>
eu_rights_str_mv	openAccess
id	Manara_3f13c41793d2f4c2c0fc99f07f917ee1
identifier_str_mv	10.1158/1078-0432.30706779
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30706779
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final AnalysisChong Kin Liam (15331321)Azura Rozila Ahmad (15331324)Te-Chun Hsia (15331327)Jianying Zhou (15331330)Dong-Wan Kim (15036467)Ross Andrew Soo (15331333)Ying Cheng (15331336)Shun Lu (15331339)Sang Won Shin (15331342)James Chih-Hsin Yang (15048002)Yiping Zhang (15331345)Jun Zhao (11571833)Karin Berghoff (15331348)Rolf Bruns (15331351)Andreas Johne (15331354)Yi-Long Wu (11678896)CancerTherapeutic Research and DevelopmentClinical Research and TrialsChemotherapyClinical Trial ResultsClinical-Stage ResearchDrug ResistanceLung CancerPrecision MedicineSmall Molecule Agents<p>Outcomes of treatment for the patient subgroup with MET overexpression</p>2025-11-25T13:01:32ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30706779https://figshare.com/articles/figure/Supplementary_Figure_S3_from_Randomized_Trial_of_Tepotinib_Plus_Gefitinib_versus_Chemotherapy_in_i_EGFR_i_-Mutant_NSCLC_with_EGFR_Inhibitor_Resistance_Due_to_i_MET_i_Amplification_INSIGHT_Final_Analysis/30706779CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307067792025-11-25T13:01:32Z
spellingShingle	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis Chong Kin Liam (15331321) Cancer Therapeutic Research and Development Clinical Research and Trials Chemotherapy Clinical Trial Results Clinical-Stage Research Drug Resistance Lung Cancer Precision Medicine Small Molecule Agents
status_str	publishedVersion
title	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
title_full	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
title_fullStr	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
title_full_unstemmed	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
title_short	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
title_sort	Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
topic	Cancer Therapeutic Research and Development Clinical Research and Trials Chemotherapy Clinical Trial Results Clinical-Stage Research Drug Resistance Lung Cancer Precision Medicine Small Molecule Agents

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

مواد مشابهة